Drug Profile
TLX 101
Alternative Names: 124I-ACD-101; 124I-TX-101; 131I-ACD-101; 131I-IPA; 131I-TX-101; ACD-101; TLX-101; TX-101Latest Information Update: 17 Apr 2023
Price :
$50
*
At a glance
- Originator Therapeia
- Developer Telix Pharmaceuticals; Therapeia
- Class Amino acids; Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
- Mechanism of Action Apoptosis stimulants; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioblastoma
Most Recent Events
- 17 Apr 2023 Telix International plans the phase II/III IPAX-3 trial for Glioblastoma
- 11 Apr 2023 Grand Pharmaceutical Group files an IND application with the NMPA in China for Glioblastoma before April 2023
- 01 Apr 2023 Phase-I clinical trials in Glioblastoma (Combination therapy, First-line therapy) in Netherlands, Austria, New Zealand (IV) (NCT05450744)